Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Generics

Hikma ‘skinny’ label does not infringe Amarin patents

6 January 2022 Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

More on this story

Editor's picks

Editor's picks

More features